Study shows PICS as bioequivalent to Abraxane to treat breast cancer: SPARC
Team Udayavani, Nov 26, 2018, 12:54 PM IST
New Delhi: Sun Pharma’s research arm Sun Pharma Advanced Research Company (SPARC) Monday announced top-line results of the pivotal BE study for its Paclitaxel injection concentrate for suspension (PICS) which has been found to be a bioequivalent to Abraxane, used to treat metastatic breast cancer.
Paclitaxel injection concentrate for suspension (PICS) is a novel formulation of Paclitaxel developed using SPARC’s proprietary Nanotecton technology.
The company said it is targeting a new drug application with the US health regulator in the next few months. “Pivotal bioequivalence (BE) ,” SPARC said in a regulatory fling.
SPARC CEO Anil Raghavan said overall US Paclitaxel market is estimated to be about USD 700 million (IQVIA MAT Sep 2018). The current market is dominated by Cremophor-based Paclitaxel formulations, which accounts for 70 per cent of unit sales.
“With launch of novel formulations, market for nano-formulations of Paclitaxel is expected to grow,” he added. Shares of SPARC were trading 2.15 per cent at Rs 278.05 apiece on BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Surgical options for Parkinson’s disease
Breast cancer to cause a million deaths a year by 2040: Lancet commission
Will to resist temptations, achieve goals more trustworthy than using apps, study finds
Govt directs e-commerce firms to remove drinks, beverages from ‘health drinks’ category
Experiencing abuse, neglect as child linked to lifelong ill-health: Study
MUST WATCH
Latest Additions
No ordinary election, it’s to save Constitution, democracy: Rahul to Cong workers
No ordinary election, it’s to save Constitution, democracy: Rahul to Cong workers
Three assaulted for raising ‘Jai Shree Ram’ slogan in Bengaluru, four held
Bhadravathi: Truck collision causes railway disruption
Election Commission declares notification for 17 Lok Sabha seats in Telangana, sparks poll battle